Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Sells 6,000 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $6.31, for a total value of $37,860.00. Following the sale, the chief operating officer now owns 521,138 shares of the company’s stock, valued at $3,288,380.78. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Tina Marriott also recently made the following trade(s):

• On Thursday, September 26th, Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.00, for a total value of $42,000.00.
• On Thursday, August 29th, Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.56, for a total value of $45,360.00.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ:RXRX traded up $0.39 during trading on Monday, hitting $6.87. 4,496,351 shares of the company traded hands, compared to its average volume of 5,710,931. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. The business’s fifty day moving average is $6.72 and its 200-day moving average is $7.70. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of -4.26 and a beta of 0.80. Recursion Pharmaceuticals, Inc. has a one year low of $4.97 and a one year high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The company had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. During the same period in the prior year, the business earned ($0.38) earnings per share. Recursion Pharmaceuticals’s quarterly revenue was up 30.9% on a year-over-year basis. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RXRX has been the topic of several recent analyst reports. Jefferies Financial Group cut their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Needham & Company LLC reduced their price target on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. Leerink Partners lowered their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Finally, KeyCorp reduced their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $9.40.

Institutional Trading of Recursion Pharmaceuticals

A number of large investors have recently modified their holdings of RXRX. Allspring Global Investments Holdings LLC bought a new position in Recursion Pharmaceuticals in the 3rd quarter worth about $25,000. GAMMA Investing LLC boosted its position in shares of Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after buying an additional 6,036 shares during the period. Amalgamated Bank grew its holdings in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after buying an additional 2,459 shares in the last quarter. San Luis Wealth Advisors LLC acquired a new stake in Recursion Pharmaceuticals in the 3rd quarter valued at approximately $69,000. Finally, Vontobel Holding Ltd. bought a new stake in Recursion Pharmaceuticals during the 3rd quarter valued at $70,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.